Japanese Patient and Physician Preferences for Systemic Therapy Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Discrete Choice Experiment
Not Applicable
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-jRCT1030220517
- Lead Sponsor
- Kitagawa Hiroshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 210
Inclusion Criteria
[Patients]
1.Japanese patient aged 18 years or older at the time of informed consent
2.Has HCC history and has undergone TACE within 5 years from the time of informed consent
3.Can understand written Japanese
4.Has undergone systemic therapy (for qualitative survey only)
[Physicians]
1.Hepatologist with a Japanese medical license and enough experience treating HCC in Japan (i.e., average 5 patients / year in the last 3 years)
2.Can understand written Japanese
Exclusion Criteria
[Patients]
Patient or family member residing with the patient works in pharmaceutical, medical, or market research industries
[Physicians]
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -Preference weight (strength) given to each attribute with its 95% confidence interval (CI) for patients and physicians.<br>-Relative importance of the levels of each attribute.
- Secondary Outcome Measures
Name Time Method Treatment preference weight relative to patients' and physicians' characteristics for each attribute and 95% CI.